The Bacterial Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bacterial partnering deals and agreements entered into by the worlds leading healthcare companies
Several companies are rumored to be competing to acquire Omega Pharma, the fastest growing consumer healthcare company in the U.K. and Ireland.
The timing may be right for a takeover of Cubist Pharmaceuticals.
This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in June 2014.
The term antibiotics was first used in 1942 by Selman Waksman and his collaborator
Novartis is a top pharmaceutical company based in Basel, Switzerland
The Medicines Company is a global biopharmaceutical company currently ranked at no.21 in the global biotechnology top 50. The company develops medical solutions for acute and intensive care in hospitals and is aiming to become a leader in this area.
Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan
Cubist, a leading biopharmaceutical company focusses in the discovery, development and commercialization of novel acute care therapies.
This month we provide you with an overview of deal analysis life science deal making activity, covering partnering, M&A and financing in February 2014
This month we provide you with an overview of deal analysis life science deal making activity, covering partnering, M&A and financing in January 2014
Sorry, your search returned no results.
Forest Laboratories, a big pharma company is paying Nabriva Therapeutics $25 million in a co-development deal for Nabriva’s antibacterial agent, BC-3781, and the right to acquire Nabriva over the next 12 months
BioRelix will apply its proprietary riboswitch technology platform to identify compounds with activity against a number of bacterial targets. The parties will jointly undertake preclinical programs, and Merck will subsequently be responsible for clinical evaluation of any candidates chosen for further development.
Under two agreements, PPD in-licensed the two assets and will advance the compounds through Phase II development.
Symbiomix Therapeutics announced multiple milestones, including the closing of the third and final tranche of a $41 million Series A financing and positive results from a multi-center, randomized Phase 2 trial testing a single oral dose of SYM-1219 for the treatment of bacterial vaginosis (BV).
Nabriva Therapeutics announced the successful completion of a $120 million Series B financing
The Bill & Melinda Gates Foundation and CureVac announced that the foundation has made a commitment to invest $52 million (€46 million) in CureVac
GSK has acquired GlycoVaxyn
Melinta Therapeutics has entered into a $30 million growth capital debt financing agreement with Hercules Technology Growth Capital
Actavis and Durata Therapeutics have inked a definitive agreement to acquire Durata Therapeutics for $675 million.